Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2026 05:20 ET | Source: ALK Abello

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.
February 20, 2026 08:55 ET | Source: ALK Abello

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026

Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede...
February 20, 2026 08:55 ET | Source: ALK Abello

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The...
February 20, 2026 01:32 ET | Source: ALK Abello

Henriette Mersebach fratræder som forskningsdirektør i ALK

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23....
February 20, 2026 01:32 ET | Source: ALK Abello

Henriette Mersebach to step down as ALK’s head of R&D

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management,...
February 20, 2026 01:18 ET | Source: ALK Abello

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained...